The widening net loss and accelerating cash burn without any clinical data catalyst are negative for the stock. The $0.54 EPS miss vs $0.36 consensus is a significant disappointment for a pre-revenue biotech. Monitor for the first clinical data readout from Ntrust-1 and Ntrust-2, expected at a medical conference in 2026, as the next potential catalyst.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $2.33entry
- T+1 · 3mo ago +2.58%α +2.32% · $2.39
- T+5 · 3mo ago +3.43%α +3.84% · $2.41
- T+20 · 2mo ago +24.89%α +25.95% · $2.91
- T+60 · 13d ago −25.75%α −25.26% · $1.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of -$0.36 per share. The net loss widened to $40.4 million from $23.0 million a year ago, driven by a 59% increase in operating expenses, including an $8.0 million impairment charge. Cash burn accelerated, with cash and investments declining to $243.2 million from $295.1 million at year-end 2025, though the company maintains a cash runway into 2029. No clinical data catalysts were announced, with initial data still expected at a medical conference in 2026.
Key Financial Metrics
Key Facts
- Net loss per share was -$0.54 vs consensus -$0.36, a 48.6% miss.
- Net loss widened to $40.4M in Q2 2026 from $23.0M in Q2 2025.
- Operating expenses surged 59% YoY to $43.1M, including an $8.0M impairment charge.
- Cash and investments fell to $243.2M from $295.1M at Dec 31, 2025, a $51.9M decline in six months.
- Cash runway guidance unchanged, expected to fund operations into 2029.
- No clinical data update; initial Ntrust-1 and Ntrust-2 data still planned for a medical conference in 2026.
Financial Impact
Net loss per share of -$0.54 missed consensus of -$0.36 by $0.18 per share. Net loss increased $17.4M YoY to $40.4M.
Risk Factors
- No approved products or revenue; continued operating losses.
- Cash burn accelerated to ~$26M/quarter in H1 2026 from ~$18M/quarter in H1 2025.
- Clinical-stage risk, NKX019 may fail to demonstrate efficacy or safety in ongoing trials.
- Potential need for future dilutive financing if cash runway shortens.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342402 |
| Document: nktx-20260810.htm | 0001193125-26-342402 |
| Document: 0001193125-26-342402-index-headers.html | 0001193125-26-342402 |
| Document: 0001193125-26-342402-index.html | 0001193125-26-342402 |
| Document: 0001193125-26-342402.txt | 0001193125-26-342402 |
| 8-K Data (Synthetic) | 0001193125-26-342402 |
Track record
13 reports on NKTX
5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
- Aug 10, 202614w ago 8-K Bearish 6/10 Viewing Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
- May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
- Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
- Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
- Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers